U.S. License Holder:
Date of License:
aBLA submitted to FDA November-2022
ABP 654 (ustekinumab) is not FDA-approved. An aBLA has been submitted to the FDA.
U.S. Patent LitigationsPACER
U.S. Patent Nos.
6,902,734 (Anti-IL-12 Antibodies and Compositions Thereof) 8,852,889 (Cell Culture Process) 9,217,168 (Methods of Cell Culture) 9,475,858 (Cell Culture Process) 9,663,810 (Methods of Cell Culture) 10,961,307 (Methods of Treating Moderately to Severely Active Ulcerative Colitis by Administering an Anti-IL12/IL23 Antibody)
Janssen Biotech, Inc.
Stipulated Dismissal Due to Settlement